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Available online 16 October 2012Abstract Objective. Fecal incontinence reduces the quality of life of many women but has no long-term cure. Research on
mesenchymal stem cell (MSC)-based therapies has shown promising results. The primary aim of this study was to evaluate
functional recovery after treatment with MSCs in two animal models of anal sphincter injury.
Methods. Seventy virgin female rats received a sphincterotomy (SP) to model episiotomy, a pudendal nerve crush (PNC) to
model the nerve injuries of childbirth, a sham SP, or a sham PNC. Anal sphincter pressures and electromyography (EMG) were
recorded after injury but before treatment and 10 days after injury. Twenty-four hours after injury, each animal received
either 0.2 ml saline or 2 million MSCs labelled with green fluorescing protein (GFP) suspended in 0.2 ml saline, either
intravenously (IV) into the tail vein or intramuscularly (IM) into the anal sphincter.
Results. MSCs delivered IV after SP resulted in a significant increase in resting anal sphincter pressure and peak pressure, as
well as anal sphincter EMG amplitude and frequency 10 days after injury. MSCs delivered IM after SP resulted in a significant
increase in resting anal sphincter pressure and anal sphincter EMG frequency but not amplitude. There was no improvement in
anal sphincter pressure or EMG with in animals receiving MSCs after PNC. GFP-labelled cells were not found near the external
anal sphincter in MSC-treated animals after SP.
Conclusion. MSC treatment resulted in significant improvement in anal pressures after SP but not after PNC, suggesting that
MSCs could be utilized to facilitate recovery after anal sphincter injury.
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Psychological and social ostracism are common issues that
patients debilitated by fecal incontinence (FI) encounter
(Lazarescu et al., 2009). Although the cause of anal sphincter
incontinence is multi-factorial (Kouraklis and Andromanakos,
2004; Safioleas et al., 2008), the prevalence is known to be
higher in women due to childbirth injuries (Pretlove et al.,
2006). However, the clinical manifestations of FI may not
occur at the time of injury but most often manifest years later
(Halverson and Hull, 2002).
Surgical repair is one of the treatments for a damaged anal
sphincter; however, sphincter function deteriorates over time
and long-term outcome remains unsatisfactory (Gutirrez et
al., 2003; Halverson and Hull, 2002; Karoui et al., 2000; Malouf
et al., 2000; Zutshi et al., 2009b). Newer treatment options
include neuromodulation (Hosker et al., 2007), the Secca
procedure (Takahashi-Monroy et al., 2008), bulking agents
(Chan and Tjandra, 2006; Kenefick et al., 2007) and an
artificial bowel sphincter (Altomare et al., 2009). Themultiple
treatment options and unsatisfactory long-term outcomes
point to the need for innovative treatments for FI that have
long-term durability.
Several studies have investigated the role of mesenchymal
stem cells (MSCs) in improving anal sphincter function after
direct injection of stem cells to the anal sphincter muscles
(Kajbafzadeh et al., 2010; Kang et al., 2008; Lorenzi et al.,
2008; Pathi et al., 2012). The results of these studies are
promising; however, only ex vivo outcomes were utilized and
the in vivo effects on anal pressures were not assessed. Pathi
et al. (2012) investigated the effect of IV and direct injection
on neurophysiology studies and studied mRNA levels of
anti-inflammatory genes, genes highly expressed after an
acute and genes involved in matrix synthesis as a function of
time. In addition, investigations in animal models of heart
failure demonstrate a therapeutic effect of MSCs infused
intravenously (IV), which may provide a less invasive delivery
route for MSCs than those previously tested for treatment of FI
(Shabbir et al., 2009a, 2009b).
We have developed rat models of anal sphincter dysfunction
induced via sphincterotomy (SP), or pudendal nerve injury to
model the nerve injuries of childbirth, and have demonstrated
changes in anal sphincter pressures in vivo lasting up to 4 weeks
after the injury (Salcedo et al., 2010). We have also demonstrat-
ed upregulation of MCP-3 and SDF-1 in the anal sphincter
complex after injury (Salcedo et al., 2011). The goal of this
project was to investigate the changes in anal sphincter pressure
after IV or intramuscular (IM) injection of MSCs in our previously
established animalmodels,with the long-termgoal of developing
improved therapy for patients with FI.Material and methods
This study was approved by the Cleveland Clinic Institutional
Animal Care and Use Committee.Mesenchymal stem cell harvesting and cell culturing
Virgin female Sprague–Dawley rats were euthanized and bone
marrow was harvested from the tibia and femurs by gentlyflushing the bone with 1 ml Dulbecco's modified Eagle medium
(DMEM, Invitrogen, Carlsbad, CA, USA). To separate adherent
cells, bone marrow clumps were passed through 18 and 20
gauge needles. The cells were centrifuged at 2500 rpm for
5 min with three changes of PBS. The washed cells were placed
in a vented cell culture T75 flask (3151 Costar, Corning
Incorporated, Corning, NY)with 25 ml DMEM (Gibco, Invitrogen
Corp., USA) containing 10% FBS and 1% antibiotic and
anti-mycotic solution (Gibco 15240, Invitrogen Corp., USA)
and were incubated at 37 °C. At this stage, the cells were
identified as P0. Themediawas changed 3 days later to remove
non-adherent cells. Succeeding media changes were made
every 3–4 days according to cellular confluence. At 70–80%
confluence, the adherent cells were detached after incubation
with 0.05% trypsin and 2 mM EDTA for 5–10 min.
At passage P4, cultures were negatively selected for MSC.
Cell sorting for MSC was performed with an EasySep pyco-
erythrin (PE) selection kit according to the manufacturer's
instructions (Stem Cell Technologies, Vancouver, B.C.,
Canada). The cultures were simultaneously depleted of
CD45+ and CD34+ cells using 10 μl of each of the primary
PE-conjugated antibodies: mouse anti-rat CD45+ (BD
Biosciences, San Diego, CA, USA) and mouse anti-CD34+
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for
every 106 cells.
Green fluorescent protein (GFP) labelling
After sorting and MSC selection, when the cells reached 80–90%
confluence, MSCs were transfected with a lentivirus vector
pCCLsin.ppt.hPGK.GFP.pre (a generous gift from the Cossu
Lab), which uses a human PGK promoter to constitutively
express green fluorescent protein (GFP), and were processed
overnight by incubation in a mixture of normal medium (6 ml),
polybrene (6 μl) and 10×MOI (10 million viruses for eachmillion
cells). Transduction proceeded overnight and the medium was
changed after 6–8 h incubation. MSC were checked for GFP-
labelled cells under immunoflouroscopy and expanded until
P12–20 when they were utilized for the study. Cultures were
then trypsinized and spun at 2500 rpm for 5 min. Cells were
resuspended in PBS (0.2 ml for 2 million cells) for animal
experiments.
Animal models
Seventy age-matched female Sprague–Dawley rats weighing
240–260 g were randomly allocated into the following groups:
sphincterotomy (SP; n=20), pudendal nerve crush (PNC; n=20),
sham SP (n=10) and sham PNC (n=20). SP was performed under
ketamine (100 mg/kg) and xylazine (10 mg/kg) i.p. anesthesia
by incising the external and internal anal sphincters 2–3 mm
deep, as we have done previously (Zutshi et al., 2009a). Anal
sphincter transection was confirmed with a dissecting
microscope. Since the anal sphincter in the rat is small and
superficial, even a minute incision could incorporate a part
of the anal sphincter. Therefore, sham SP was created by
pressing a Q-tip on the anal sphincter for 5 s.
PNC was performed under the same anesthesia via a
posterior incision in the sacro-coccygeal area. The pudendal
nerves were isolated bilaterally in the ischiorectal fossa and
crushed twice for 30 s each with a Castroviejo needle holder,
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2009a). Sham PNC was created by making a similar incision in
the sacro-coccygeal area and gently opening the ischiorectal
fossa bilaterally without crushing the pudendal nerve.
MSC treatment
Twenty-four hours after injury, animals in each injury group
received either 2 million MSC in 0.2 ml PBS (Sphincterotomy
n=10 (IM AND IV) and pudendal nerve crush n=10 (IM and IV)
sham SP n=10 (IM AND IV) and sham PNC n=10 (IM and IV)
total n=40) or PBS without MSCs (Sphincterotomy n=10 (IM
and IV), PNC n=10 (IM and IV) and sham PNC n=10 (IM and IV)
total n=30) either IM in the anal sphincter via 4 injections, ¼
dose in each circumferential quadrant (n=35), or intrave-
nously (IV) via the tail vein (n=35). This time point was
selected since we have previously found that the stem cell
homing cytokines SDF-1 and MCP-3 are maximally elevated
24 h after injury (Salcedo et al., 2011).
Functional testing
Anal pressure (basal pressure) and anal sphincter electromy-
ography (EMG) were performed after injury but before
treatment, as well as 10 days after injury (9 days after
treatment) in all animals, as we have done previously (Zutshi
et al., 2009a). Under ketamine and xylazine anesthesia,
resting anal pressure was measured using a saline filled
balloon (Kent Scientific, Torrington, CT; size 4) inserted
superficially in the anal sphincter and, via tubing (PE-90),
connected to a pressure transducer (Grass Astromed, PT300,
Warwick, RI), a digital amplifier (Astromed Inc, Model P122),
and digital data recording system (Dash 8x, Astromed Inc.) as
in our previous studies (Zutshi et al., 2009a). Anal sphincter
electromyography (EMG) data were recorded simultaneously
with anal sphincter pressures by placing a 30 G concentric
needle electrode (Viasys Healthcare, Hawthorne, NY) in the
external anal sphincter at the left posterolateral position. Ten
days after injury, functional testing of both resting anal
pressures and EMG was repeated under anesthesia, after
which the animals were euthanized with an overdose of
pentobarbital (200 mg/kg) i.p.
Immunofluorescence
The anal sphincter complex was dissected, immersion fixed in
formalin, paraffin embedded, sectioned (5 μm) and prepared
for immunofluorescence studies to localize MSC via GFP.
Antigen retrieval was performed by incubating the sections in
10 mM sodium citrate buffer (pH 6.0) at 95 °C for 1 h, then
cooled for 20 min. The slides were then washed in PBS for
5 min three times at room temperature. Slides were then
incubated with 1% universal blocking buffer for 3 h at 37 °C to
reduce any non-specific binding of IgG. Slides were then
incubated overnight with rabbit anti-GFP (SC 8334, Santa Cruz
Biotechnology; 1:200) and mouse anti-smooth muscle α-actin
(SC 1306, Santa Cruz Biotechnology; 1:30) antibodies over-
night at 4 °C. Slides were thenwashedwith PBS and incubated
for 2 h with Alexa Fluor 488 (A21206, Invitrogen Corp.; 1:800).
The slides were again washed with PBS then incubated for 2 h
with goat-anti-mouse IgG Texas red (SC 2781, Santa CruzBiotechnology; 1:100). After extensive washing with PBS, the
cover slips were mounted with aqueous mounting medium
(Vectashield Mounting Medium) with DAPI (4′,6-diamidino-
2-phenylindole) as a nuclear counterstain (H-1200; Vector
Laboratories, Burlingame, CA, USA).
Tissues were analyzed using an upright spectral laser
scanning confocal microscope (Model TCS-SP Leica Micro-
systems, Heidelberg Germany). GFP-positive cells were count-
ed per 20× field and scanned for 10 fields.
Data analysis
Anal pressure data was analyzed to determine resting pressure
(RP), the baseline anal pressure at the start of each recording
and peak contraction pressure (PC), and the maximum anal
pressure during anal contraction. Three typical pressure
waves were analyzed before treatment and 10 days after
treatment. A mean was taken of each variable in each animal
and used in further group analysis (Salcedo et al., 2010).
EMG activity was quantified using mean amplitude and
frequency as we have done previously (Salcedo et al., 2010;
Zutshi et al., 2009a). Three 5 s intervals were segmented
from the EMG at each time point after injury. The mean of
the rectified signal for each 5 s interval was calculated to
obtain amplitude (Myosotic™ SignaPoint 2007, Myosotic LLC,
Woodenville, WA). To find the frequency of the signal, a
threshold was calculated in the uninjured state of sham PNC
animals that received PBS treatment in the absence of
pressure contraction, and was set above the noise amplitude
but below the amplitude of motor unit action potentials.
Subsequently, we counted the number of threshold cross-
ings. Half the number of threshold crossing was taken as an
estimate of firing rate and their frequency was calculated.
The mean of each variable in each animal was calculated and
used in further group analysis.
Statistically significant differences in EMG amplitude and
frequency as well as in anal pressures between groups at
each of the two time points and between time points were
determined using a one way ANOVA with a Tukey–Kramer
post-hoc test for pairwise comparisons. Pb0.05 indicated a
significant difference between experimental groups. Values
are presented as mean±standard error of the mean (SEM).
Immunofluorescence data was analyzed quantitatively in a
blinded fashion.
Results
No mortality was reported in any of the treatment arms.
Anal sphincter pressures
Neither resting pressure nor peak pressure of the anal
sphincter complex was significantly different between groups
after injury but before treatment. However, resting pressure
was significantly greater 10 days after SP in animals treated
with MSCs compared to those treated with PBS, via either IM
(p=0.04) (Fig. 1 top) or IV (p=0.01) (Fig. 1, bottom) routes of
administration. Resting pressures of the sham SP animals were
not significantly different from that of animals that received
SP and cells or PBS.
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the SP group treated with MSCs delivered IM from 7.6±0.3 cm
H2O after injury but before treatment to 13.9±1.5 cm H2O
9 days after treatment, peak pressure in MSC-treated animals
with SP was not significantly greater than peak pressure in
PBS-treated animals with SP (p=0.09). Peak pressure was
significantly greater 9 days after treatment with MSC delivered
IV after SP than 9 days after IV PBS treatment of SP (p=0.04).
Resting pressure of the anal sphincter was significantly
decreased 10 days after PNC compared to 10 days after sham
PNC, when both were treated with PBS (p=0.01). Both PNC and
sham PNC groups treated with MSCs delivered IV had resting
pressure between that of PNC and sham PNC treated with PBS
and were not significantly different from either (Fig. 2,
bottom). Therewere no significant differences in either resting
or peak pressure of the anal sphincter after PNC treated with
MSC or PBS, IM or IV.
Anal sphincter EMG
Neither amplitude nor frequency of anal sphincter EMG was
significantly different between groups after injury but before
treatment.Figure 1 Anal sphincter pressures in animals 10 days after
sphincterotomy (SP, n=10) or sham SP (n=10). Resting anal
sphincter pressure in animals treated with intravascular (IV,
n=5 (top) or intramuscular (IM, n=5 bottom) administration
of mesenchymal stem cells (MSC) or saline (PBS, n=5).
* indicates a significant difference compared to comparable
saline treated group.Animals undergoing a sphincterotomy: Rats with SP treated
with PBS had decreased external anal sphincter EMG amplitude
9 days after treatment compared to either rats with SP or rats
with sham SP treated with MSCs. (Fig. 3) However, this
difference was only significantly different between sham SP
rats treated with MSCs delivered IM and SP rats treated with
PBS given IM (pb0.001) and between rats with SP treated IV
with PBS and rats with SP treated IV with MSCs (p=0.02).
Frequency of external anal sphincter EMG, in contrast, was
significantly decreased 9 days after PBS treatment compared
to 9 days after MSC treatment via either IM (p=0.04) or IV (p=
0.003) routes of administration (Fig. 4).
Animals undergoing a pudendal nerve crush: Although rats
with PNC treated with MSCs had consistently greater external
anal sphincter EMG amplitude (Fig. 5) and frequency (Fig. 6)
than rats with PNC treated with PBS, these differences were
not significantly different.
Immunofluorescence
Qualitative analysis under confocal microscopy did not show
GFP-positive cells in the anal sphincter after either IM or IVFigure 2 Anal sphincter pressures in animals 10 days after
pudendal nerve crush (PNC, n=10) or sham PNC (n=10). Resting
anal sphincter pressure in animals treated with intravascular
(IV, n=5) (top) or intramuscular (IM, n=5) (bottom) administra-
tion of mesenchymal stem cells (MSC) or saline (n=5). * indicates
a significant difference compared to comparable saline (PBS)
treated group.
Figure 3 EMG amplitude in animals treated with intramuscu-
lar (IM, n=15) (top) and intravascular (IV, n=15) (bottom)
injection of saline (control) or MSC 10 days after anal
sphincterotomy (SP, n=20) and sham injury (Sham SP, n=10).
MSC, mesenchymal stem cells; PBS, saline. * indicates a
significant difference compared to comparable saline (PBS)
treated group. + indicates a significant difference compared to
before treatment.
Figure 4 EMG frequency in animals treated with intramuscu-
lar (IM, n=15) (top) and intravascular (IV, n=15) (bottom)
injection of saline (control) or MSC 10 days after anal
sphincterotomy (SP, n=20) and sham injury (Sham SP, n=10).
MSC, mesenchymal stem cells; PBS, saline. * indicates a
significant difference compared to comparable saline (PBS)
treated group. + indicates a significant difference compared to
before treatment.
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PNC 9 days after injury.Discussion
Lack of encouraging long-term outcomes for FI has prompted
the search for innovative procedures (Altomare et al., 2009;
Caplan and Dennis, 2006b; Hosker et al., 2007) and cell-based
therapies have shown promising results in animal studies
(Lorenzi et al., 2008; White et al., 2010). Stem cell therapy in
gastrointestinal disease has been explored in familial adeno-
matous polyposis (Leedham et al., 2005) and in inflammatory
bowel disease (Armaka et al., 2008). Several cell-based
therapies are presently in clinical trials for treatment of
pathologies of other organ systems, such as cardiac (Karussis
et al., 2010; Perin et al., 2011), urinary (Furuta et al., 2007;
Stangel-Wojcikiewicz et al., 2010), limb ischemia (Walter et
al., 2011), amyotrophic lateral sclerosis (Mazzini et al., 2011)
and multiple sclerosis (Karussis et al., 2010). This approachhas motivated several researchers to create animal models of
FI for pre-clinical testing of cell-based therapies (Kang et al.,
2008; Lorenzi et al., 2008).
Healy et al. (2008) have developed a neurogenic model of
FI, whileWhite et al. (2010) tested the utility ofmyogenic stem
cells for repair after anal sphincter transection and found that
injection of myogenic stem cells at the time of repair resulted
in enhanced contractility 90 days later compared with a repair
alone. The results of this research can provide a better
understanding of regenerative cell-based therapy; however,
there is a need to further investigate the mechanisms that
promote repair to optimize the results when translated.
Stem cell homing is an active process of migration of the
stem cells through the vascular endothelium to a site and
target organ (Lapidot et al., 2005). SDF-1 and MCP-3 have been
identified as potential homing factors that are upregulated
after myocardial infarction (Schenk et al., 2007). Studies have
shown improvement in cardiac function with successful
Figure 5 EMG amplitude in animals treated with intramuscu-
lar [IM, n=10 (top)] and intravenous (n=10) (bottom) injection
of saline (n=10) (control) or MSC 10 days after pudendal nerve
crush (PNC, n=20) and sham injury (Sham PNC, n=10). MSC,
mesenchymal stem cells; PBS, saline.
Figure 6 EMG frequency in animals treated with intramuscu-
lar (IM, n=10) (top) and intravascular (IV, n=10) (bottom)
injection of saline (n=10) (control) or MSC 10 days after
pudendal nerve crush (PNC) and sham injury (Sham PNC). MSC,
mesenchymal stem cells; PBS, saline.
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and MCP-3 have been implanted in infarcted myocardial tissue
(Penn, 2007). The improvement in function with MSC treat-
ment has been attributed to improvement in function of the
cells in the area surrounding the infarct (M. Zhang et al., 2007).
Schenk et al. (2007) demonstrated engraftment of MSCs
1 month after injury, when homing was re-established by
overexpressing SDF-1 at the site of the previous myocardial
infarction.
The goals of the current study were to investigate the
changes in anal sphincter pressure after IV or IM injection of
MSCs in our previously established animal models. Our models
(Salcedo et al., 2010; Zutshi et al., 2009a) allow measurement
of anal sphincter pressure and EMG in vivo in a repeated,
survival fashion, a useful attribute since our ultimate aim is to
reinforce the anal sphincter complex with cell therapy. The
results suggest that some of the deterioration of resting anal
sphincter pressures after SP was preventable by treatment with
MSCs. IV infusion appears to provide amore effective route than
IM administration, which may have caused MSC retention in the
lymphatic circulation (H. Zhang et al., 2007). This is in contrast
to the findings of Pathi et al. (2012) who found increased levelsof matrix synthesis genes TGF-β1 and lysyl oxidase only in
animals receiving direct injection.
MSCs delivered either IV or IM did not appear to facilitate
recovery from PNC. It is possible that the trophic effect
mediated by the MSCs at the time points we studied could
have been too subtle to be observed by our physiologic
recordings. This could be secondary to the fact that nerve
injuries do not cause significant muscular physiologic changes
until several weeks later (Campbell, 2008). Based on our
previous animal model investigations, a denervation injury
causes significant changes to anal sphincter pressure and EMG
due to anal sphincter atrophy (Salcedo et al., 2010; Zutshi et
al., 2009a). Future research should be aimed at investigating
pudendal nerve recovery over a longer time course, particu-
larly considering that clinical trials using cells to treat stress
urinary incontinence show a delay to functional improvement
after treatment (Stangel-Wojcikiewicz et al., 2010).
In animals receiving a sphincterotomy followed by IV MSC
therapy, green fluorescing MSCs were not observed in the
external and internal anal sphincters. This is similar to the
findings of Pathi et al. (2012). The increase in the anal pressure
compared to the controls thus suggests that MSCsmay have had
a short term engraftment and had a local effect via secretion of
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2009b). This finding is also similar to that observed by Schenk et
al. (2007) and M. Zhang et al. (2007) who demonstrated in a
cardiac model that cardiac function improved without new
tissue formation. They attributed the functional improvement
to trophic factors released by MSCs that home to the site of
injury. Studies by Shabbir et al. (2009b) and others (Caplan and
Dennis, 2006b) have similarly shown improvement in cardiac
myocyte regeneration and demonstrated that stem cells
produce trophic cellular mediators like HGF, IGF-II and VEGF
responsible for physiologic changes. Shabbir et al. have also
shown that MSC administration increases bone marrow progen-
itor cells along with increased myocardial progenitor cells.
Therefore, we postulate that as of yet unknown chemotactic
secretions by the MSCs could be the source of the improve-
ments observed in our study. We have demonstrated the
upregulation of MCP-3 and SDF-1 (Salcedo et al., 2011) after
anal sphincter injury and have documented in vitro-migration
of MSCs towards SDF-1 and MCP-3 (unpublished data). More
research is needed to evaluate the molecular mechanisms
leading to functional improvement with MSCs treatment.
Other studies that evaluated MSCs for improving anal
continence used in vitro muscle contractility testing, and
concluded that MSCs provide a beneficial effect when used as
a cellular therapy (Kang et al., 2008; Lorenzi et al., 2008;
Pathi et al., 2012; White et al., 2010). Although the
mechanisms of this effect were not elucidated, the main
premise is that MSCs provide a useful therapeutic adjunct for
improving anal sphincter function (Kajbafzadeh et al., 2010).
A study by White et al. (2010) confirms that injection of
myogenic stem cells at the time of external anal sphincter
repair results in improvement of function, while the same
group (Pathi et al., 2012) demonstrated evidence of
increased collagen bundles in animals injected directly with
MSCs with increase in both TGF-β 1 and lysyl oxidase mRNA.
They, however, did not find GFP-labelled cells in the area
beyond 7 days in these animals.
A limitation of the study is the potential bias of the IV
approach of administration. The proximity of the tail vein to
the anal sphincter may suggest that MSCs could be trapped
during their systemic course. Ours was an initial study and a
longer time course of recovery is underwaywith different doses
and timing of MSC administration. In addition, since FI often
develops years or decades after the initial injury, treatment
with MSCs at a time remote from injury needs to be
investigated, along with methods to upregulate homing
cytokines at this later time (Abbott et al., 2004; Chavakis and
Dimmeler, 2011; Chavakis et al., 2008; Ghadge et al., 2011;
Kuliszewski et al., 2011; Ma et al., 2005). The mechanism of
action of MSCs ought to be investigated in these studies.
Another limitation is the short time period that the study
involved. As this was a pilot study to test our hypothesis that
MSCs do home to the anal sphincter and because we have
demonstrated the process of repair to be demonstrated by
2 weeks we chose 10 days as the time to test the hypothesis.
A future study involves an extended time period to study
longer time changes after MSC mediated repair and to look
for engraftment vs. new tissue formation due to paracrine
effects.
We also did not use fibroblasts as a negative control as
done in cardiac studies. This field is not investigated enough
in the anal sphincter for a true population of cells to bedefined. Other researchers have used other cell types such
as muscle derived stem cells (Kang et al., 2008) with some
good results. Further investigation into the mechanism of
action is warranted.Conclusion
MSC treatment either IM or IV resulted in improved anal
sphincter pressures after a direct injury to the anal sphincter
complex. The possible secretion of unknown chemotactic
factors by MSCs that were present at the site of injury could
have contributed to this improvement in resting anal pressures
after IV MSC treatment. Only after IV MSC treatment of
sphincterotomy was the improvement in EMG significant. MSC
administration after pudendal nerve crush did not result in
functional improvement and requires further investigation
into changes in the timing of MSC therapy as well as the
mechanism of regeneration after a nerve injury.Acknowledgments
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